Article

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

2022-11-28

Abstract excerpt

<title>Abstract</title> <p>Background A pharmacogenomic platform using patient-derived cells (PDCs) was established to identify the underlying resistance mechanisms and tailored treatment for patients with advanced or refractory lung cancer. Methods Drug sensitivity screening and multi-omics datasets were acquired from lung cancer PDCs (n = 102). Integrative analysis was performed to explore drug candidates acc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 918af48c-7621-51ed-b0a4-d9b1e92b24a7
DOI: 10.21203/rs.3.rs-2295528/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancerDOI 10.21203/rs.3.rs-2295528/v1Read

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.Semantic proximity Read

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patientsSemantic proximity Read

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients.Semantic proximity Read

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.Semantic proximity Read

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentitySemantic proximity Read

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized MedicineSemantic proximity Read

Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunitiesSemantic proximity Read

Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.Semantic proximity Read

Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma.Semantic proximity Read

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to TherapySemantic proximity Read

Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-ResistanceSemantic proximity Read

Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma.Semantic proximity Read